Is IMRX or MCRB more profitable?

Immuneering's return on equity of -31.93% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Immuneering N/A -31.93% -29.92% Seres Therapeutics N/A -130.29% -35.35%

Does the media refer more to IMRX or MCRB?

In the previous week, Immuneering had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 3 mentions for Seres Therapeutics. Immuneering's average media sentiment score of 0.86 beat Seres Therapeutics' score of 0.47 indicating that Immuneering is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immuneering 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is MCRB or NVCT more profitable?

Seres Therapeutics' return on equity of -130.29% beat Nuvectis Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Seres Therapeutics N/A -130.29% -35.35% Nuvectis Pharma N/A -161.00% -98.88%

Does the media prefer MCRB or NVCT?

In the previous week, Seres Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.31 beat Seres Therapeutics' score of 0.47 indicating that Nuvectis Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvectis Pharma 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MCRB or AKBA?

In the previous week, Seres Therapeutics and Seres Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.93 beat Seres Therapeutics' score of 0.47 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SRZN or MCRB more profitable?

Seres Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Seres Therapeutics' return on equity of -130.29% beat Surrozen's return on equity. Company Net Margins Return on Equity Return on Assets Surrozen -4,810.50% -4,055.04% -154.08% Seres Therapeutics N/A -130.29% -35.35%

Does the media refer more to SRZN or MCRB?

In the previous week, Surrozen had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for Seres Therapeutics. Surrozen's average media sentiment score of 0.93 beat Seres Therapeutics' score of 0.47 indicating that Surrozen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Surrozen 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend NLTX or MCRB?

Seres Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 308.92%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Neoleukin Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neoleukin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Seres Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NLTX or MCRB more profitable?

Neoleukin Therapeutics' return on equity of -37.22% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neoleukin Therapeutics N/A -37.22% -30.91% Seres Therapeutics N/A -130.29% -35.35%

Seres Therapeutics (MCRB) Competitors

$5.38 -0.32 (-5.61%)

As of 01:03 PM Eastern

Compare

MCRB vs. IMRX, NVCT, AKBA, SRZN, and NLTX

Should you buy Seres Therapeutics stock or one of its competitors? MarketBeat compares Seres Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Seres Therapeutics include Immuneering (IMRX), Nuvectis Pharma (NVCT), Akebia Therapeutics (AKBA), Surrozen (SRZN), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical products" industry.

How does Seres Therapeutics compare to Immuneering?

Immuneering (NASDAQ:IMRX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings.

In the previous week, Immuneering had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for Immuneering and 3 mentions for Seres Therapeutics. Immuneering's average media sentiment score of 0.86 beat Seres Therapeutics' score of 0.47 indicating that Immuneering is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immuneering	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Seres Therapeutics has higher revenue and earnings than Immuneering. Immuneering is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immuneering	N/A	N/A	-$56.03M	-$1.17	N/A
Seres Therapeutics	$790K	65.92	$5.70M	-$5.17	N/A

Immuneering has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Immuneering's return on equity of -31.93% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immuneering	N/A	-31.93%	-29.92%
Seres Therapeutics	N/A	-130.29%	-35.35%

Immuneering presently has a consensus target price of $16.50, indicating a potential upside of 286.87%. Seres Therapeutics has a consensus target price of $22.00, indicating a potential upside of 308.92%. Given Seres Therapeutics' higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Immuneering.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immuneering	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

67.7% of Immuneering shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 22.9% of Immuneering shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Immuneering beats Seres Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Nuvectis Pharma?

Seres Therapeutics (NASDAQ:MCRB) and Nuvectis Pharma (NASDAQ:NVCT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Seres Therapeutics has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market. Comparatively, Nuvectis Pharma has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market.

Seres Therapeutics' return on equity of -130.29% beat Nuvectis Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Nuvectis Pharma	N/A	-161.00%	-98.88%

Seres Therapeutics has higher revenue and earnings than Nuvectis Pharma. Nuvectis Pharma is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	65.92	$5.70M	-$5.17	N/A
Nuvectis Pharma	N/A	N/A	-$26.44M	-$1.31	N/A

In the previous week, Seres Therapeutics had 1 more articles in the media than Nuvectis Pharma. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for Nuvectis Pharma. Nuvectis Pharma's average media sentiment score of 1.31 beat Seres Therapeutics' score of 0.47 indicating that Nuvectis Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nuvectis Pharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics currently has a consensus target price of $22.00, indicating a potential upside of 308.92%. Nuvectis Pharma has a consensus target price of $13.00, indicating a potential upside of 17.37%. Given Seres Therapeutics' higher possible upside, analysts plainly believe Seres Therapeutics is more favorable than Nuvectis Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nuvectis Pharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 96.8% of Nuvectis Pharma shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 28.5% of Nuvectis Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Seres Therapeutics beats Nuvectis Pharma on 8 of the 12 factors compared between the two stocks.

How does Seres Therapeutics compare to Akebia Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk, valuation and media sentiment.

Seres Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -8.83%. Akebia Therapeutics' return on equity of -62.72% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	N/A	-130.29%	-35.35%
Akebia Therapeutics	-8.83%	-62.72%	-5.66%

Seres Therapeutics currently has a consensus target price of $22.00, suggesting a potential upside of 308.92%. Akebia Therapeutics has a consensus target price of $4.67, suggesting a potential upside of 406.70%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Akebia Therapeutics	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Seres Therapeutics and Seres Therapeutics both had 3 articles in the media. Akebia Therapeutics' average media sentiment score of 0.93 beat Seres Therapeutics' score of 0.47 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Seres Therapeutics has higher earnings, but lower revenue than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	65.92	$5.70M	-$5.17	N/A
Akebia Therapeutics	$236.20M	1.05	-$5.34M	-$0.08	N/A

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Seres Therapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Summary

Akebia Therapeutics beats Seres Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Seres Therapeutics compare to Surrozen?

Surrozen (NASDAQ:SRZN) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Surrozen currently has a consensus price target of $42.00, indicating a potential upside of 80.45%. Seres Therapeutics has a consensus price target of $22.00, indicating a potential upside of 308.92%. Given Seres Therapeutics' higher probable upside, analysts clearly believe Seres Therapeutics is more favorable than Surrozen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surrozen	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Seres Therapeutics has a net margin of 0.00% compared to Surrozen's net margin of -4,810.50%. Seres Therapeutics' return on equity of -130.29% beat Surrozen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surrozen	-4,810.50%	-4,055.04%	-154.08%
Seres Therapeutics	N/A	-130.29%	-35.35%

66.6% of Surrozen shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 31.7% of Surrozen shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Seres Therapeutics has lower revenue, but higher earnings than Surrozen. Seres Therapeutics is trading at a lower price-to-earnings ratio than Surrozen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surrozen	$7.49M	36.06	-$242.03M	-$37.59	N/A
Seres Therapeutics	$790K	65.92	$5.70M	-$5.17	N/A

In the previous week, Surrozen had 1 more articles in the media than Seres Therapeutics. MarketBeat recorded 4 mentions for Surrozen and 3 mentions for Seres Therapeutics. Surrozen's average media sentiment score of 0.93 beat Seres Therapeutics' score of 0.47 indicating that Surrozen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surrozen	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Surrozen has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market.

Summary

Surrozen beats Seres Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Seres Therapeutics compare to Neoleukin Therapeutics?

Neoleukin Therapeutics (NASDAQ:NLTX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Neoleukin Therapeutics' return on equity of -37.22% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neoleukin Therapeutics	N/A	-37.22%	-30.91%
Seres Therapeutics	N/A	-130.29%	-35.35%

Seres Therapeutics has a consensus target price of $22.00, suggesting a potential upside of 308.92%. Given Seres Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than Neoleukin Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neoleukin Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Seres Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Neoleukin Therapeutics has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market.

In the previous week, Seres Therapeutics had 3 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 3 mentions for Seres Therapeutics and 0 mentions for Neoleukin Therapeutics. Seres Therapeutics' average media sentiment score of 0.47 beat Neoleukin Therapeutics' score of 0.00 indicating that Seres Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Neoleukin Therapeutics	Neutral
Seres Therapeutics	Neutral

52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Seres Therapeutics has higher revenue and earnings than Neoleukin Therapeutics. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neoleukin Therapeutics	N/A	N/A	-$57.56M	-$3.11	N/A
Seres Therapeutics	$790K	65.92	$5.70M	-$5.17	N/A

Summary

Seres Therapeutics beats Neoleukin Therapeutics on 10 of the 14 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$52.08M	$3.40B	$6.50B	$12.36B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-1.04	20.08	23.99	24.69
Price / Sales	65.92	322.83	538.03	166.93
Price / Cash	5.25	53.61	27.48	37.92
Price / Book	1.10	8.06	10.47	6.82
Net Income	$5.70M	$23.89M	$3.56B	$337.45M
7 Day Performance	-14.33%	2.75%	1.21%	2.49%
1 Month Performance	-29.58%	0.70%	2.14%	4.37%
1 Year Performance	-28.27%	45.69%	26.24%	32.80%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	1.7707 of 5 stars	$5.38 -5.6%	$22.00 +308.9%	-24.0%	$52.08M	$790K	N/A	330	Gap Up
IMRX Immuneering	2.7199 of 5 stars	$3.93 -8.0%	$16.50 +319.8%	+120.5%	$254.26M	N/A	N/A	60	Analyst Downgrade
NVCT Nuvectis Pharma	1.8429 of 5 stars	$9.42 -1.3%	$10.00 +6.2%	+27.3%	$253.06M	N/A	N/A	8	Positive News Analyst Forecast Gap Up
AKBA Akebia Therapeutics	1.8689 of 5 stars	$0.94 +0.0%	$4.67 +398.8%	-74.0%	$250.90M	$236.20M	N/A	430
SRZN Surrozen	3.7704 of 5 stars	$20.69 -3.9%	$42.00 +103.0%	+146.7%	$249.85M	$7.49M	N/A	80	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. IMRX, NVCT, AKBA, SRZN, and NLTX

How does Seres Therapeutics compare to Immuneering?

Summary

How does Seres Therapeutics compare to Nuvectis Pharma?

Summary

How does Seres Therapeutics compare to Akebia Therapeutics?

Summary

How does Seres Therapeutics compare to Surrozen?

Summary

How does Seres Therapeutics compare to Neoleukin Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. IMRX, NVCT, AKBA, SRZN, and NLTX

How does Seres Therapeutics compare to Immuneering?

Does the media refer more to IMRX or MCRB?

Which has higher valuation & earnings, IMRX or MCRB?

Which has more risk and volatility, IMRX or MCRB?

Is IMRX or MCRB more profitable?

Do analysts prefer IMRX or MCRB?

Do insiders and institutionals hold more shares of IMRX or MCRB?

Summary

How does Seres Therapeutics compare to Nuvectis Pharma?

Which has more volatility and risk, MCRB or NVCT?

Is MCRB or NVCT more profitable?

Which has higher valuation and earnings, MCRB or NVCT?

Does the media prefer MCRB or NVCT?

Do analysts prefer MCRB or NVCT?

Do institutionals & insiders believe in MCRB or NVCT?

Summary

How does Seres Therapeutics compare to Akebia Therapeutics?

Is MCRB or AKBA more profitable?

Do analysts recommend MCRB or AKBA?

Does the media prefer MCRB or AKBA?

Which has stronger earnings & valuation, MCRB or AKBA?

Do insiders & institutionals hold more shares of MCRB or AKBA?

Which has more volatility & risk, MCRB or AKBA?

Summary

How does Seres Therapeutics compare to Surrozen?

Do analysts recommend SRZN or MCRB?

Is SRZN or MCRB more profitable?

Do insiders and institutionals have more ownership in SRZN or MCRB?

Which has preferable valuation & earnings, SRZN or MCRB?

Does the media refer more to SRZN or MCRB?

Which has more volatility and risk, SRZN or MCRB?

Summary

How does Seres Therapeutics compare to Neoleukin Therapeutics?

Is NLTX or MCRB more profitable?

Do analysts recommend NLTX or MCRB?

Which has more risk & volatility, NLTX or MCRB?

Does the media favor NLTX or MCRB?

Do institutionals & insiders hold more shares of NLTX or MCRB?

Which has higher valuation and earnings, NLTX or MCRB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools